Enrique Saez

US Patent:

6723531, Apr 20, 2004

Filed:

Mar 16, 1998

Appl. No.:

09/042488

Inventors:

Ronald M. Evans - La Jolla CA
David No - Irvine CA
Enrique Saez - San Diego CA

Assignee:

The Salk Institute for Biological Studies - La Jolla CA

International Classification:

C12P 2106

US Classification:

435 691, 4353201, 435325, 435455, 435 697, 424 931, 424 932, 424 9321, 514 44, 536 231, 536 235

Abstract:

In accordance with the present invention, there are provided various methods for modulating the expression of an exogenous gene in a mammalian subject employing modified ecdysone receptors. Also provided are modified ecdysone receptors, as well as homomeric and heterodimeric receptors containing same, nucleic acids encoding invention modified ecdysone receptors, modified ecdysone response elements, gene transfer vectors, recombinant cells, and transgenic animals containing nucleic acids encoding invention modified ecdysone receptor.

US Patent:

7045315, May 16, 2006

Filed:

Sep 7, 2001

Appl. No.:

09/949278

Inventors:

Ronald M. Evans - La Jolla CA, US
Enrique Saez - San Diego CA, US

Assignee:

The Salk Institute for Biological Studies - La Jolla CA

International Classification:

C12P 21/06
C12N 15/63
C07H 21/04
C07K 16/00
A01N 43/04

US Classification:

435 691, 435455, 435375, 536 231, 536 235, 536 241, 5303882, 514 44, 514178, 514609, 514614

Abstract:

In accordance with the present invention, there are provided various methods for modulating the expression of an exogenous gene in an isolated cell and in a mammalian subject employing modified ecdysone receptors. Also provided are modified ecdysone receptors, as well as homomeric and heterodimeric receptors containing same, nucleic acids encoding invention modified ecdysone receptors, modified hormone response elements, gene transfer vectors, recombinant cells, and transgenic animals containing nucleic acids encoding invention modified ecdysone receptor.

US Patent:

7846949, Dec 7, 2010

Filed:

Feb 11, 2005

Appl. No.:

10/589410

Inventors:

Valentina Molteni - San Diego CA, US
Xiaolin Li - Del Mar CA, US
Fang Liang - Carlsbad CA, US
Juliet Nabakka - Santee CA, US
Enrique Saez - San Diego CA, US
John Wityak - Carlsbad CA, US

Assignee:

IRM LLC - Hamilton

International Classification:

A61K 31/44
A61K 31/42
A61K 31/41
C07D 213/55
C07D 498/00
C07D 231/12
C07C 229/00

US Classification:

514357, 514378, 514406, 514359, 546335, 548242, 5483731, 560 41

Abstract:

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of liver X receptors (LXRs).

US Patent:

8158662, Apr 17, 2012

Filed:

Feb 11, 2005

Appl. No.:

10/589087

Inventors:

Valentina Molteni - San Diego CA, US
Xiaolin Li - Del Mar CA, US
Juliet Nabakka - Santee CA, US
David Archer Ellis - San Diego CA, US
Beth Anaclerio - San Diego CA, US
Enrique Saez - San Diego CA, US
John Wityak - Carlsbad CA, US

Assignee:

Hamilton

International Classification:

A61K 31/433
C07D 285/12

US Classification:

514363, 548136

Abstract:

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of liver X receptors (LXRs).

US Patent:

8569345, Oct 29, 2013

Filed:

Mar 7, 2012

Appl. No.:

13/414385

Inventors:

Valentina Molteni - San Diego CA, US
Xiaolin Li - San Diego CA, US
Juliet Nabakka - San Diego CA, US
David Archer Ellis - Fort Worth TX, US
Beth Anaclerio - San Diego CA, US
Enrique Saez - San Diego CA, US
John Wityak - Carlsbad CA, US

International Classification:

A61K 31/4439
A61K 31/433
C07D 417/04
C07D 417/14

US Classification:

514335, 514332, 514342, 514363, 546261, 546267, 5462687, 548136

Abstract:

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of liver X receptors (LXRs).

US Patent:

20040235169, Nov 25, 2004

Filed:

Jun 24, 2004

Appl. No.:

10/475541

Inventors:

Ronald Evans - La Jolla CA, US
Enrique Saez - San Diego CA, US
Inder Verma - La Jolla CA, US
Francesco Galimi - San Diego CA, US

International Classification:

C12N015/85

US Classification:

435/455000, 435/320100

Abstract:

The present invention provides inducible gene transfer systems and gene transfer vectors for the safe and effective transfer and expression of genes in mammalian cells, and for a very high level of control of expression of the transferred genes. The inducible gene transfer systems of the present invention may be lentiviral vectors comprising a self-inactivating 5′ LTR, a modulator-responsive promoter, a nuclear import signal, a promoter operatively associated with a nucleic acid encoding a modulator-responsive receptor, an RNA stabilizing element, and a self-inactivating 3′ LTR. Thus, the present invention provides vectors for packaging and delivering DNA to both dividing and non-dividing cells. The present invention also provides methods for treating subjects with the gene transfer systems of the present invention, and cells containing the gene transfer systems.

US Patent:

20050036992, Feb 17, 2005

Filed:

Dec 22, 2003

Appl. No.:

10/745334

Inventors:

Enrique Saez - San Diego CA, US
Peter Tontonoz - Sherman Oaks CA, US
Bryan Laffitte - Raleigh NC, US
Jing Li - La Jolla CA, US

Assignee:

IRM LLC - Hamilton
The Regents of the University of California - Oakland CA

International Classification:

A61K048/00
C12N005/08
C12N015/85

US Classification:

424093210, 435455000, 435366000

Abstract:

This invention provides novel methods for modulating expression of glut4 and other genes involved in glucose metabolism, and methods for treating or ameliorating diabetes and related diseases. The methods comprise administering to cells in a subject an effective amount of an LXR agonist and thereby modulating expression of those genes that are important for glucose uptake or gluconeogenesis. The modulation will lead to increased uptake of glucose by cells in the subject and/or reduced glucose output in the liver, and accordingly ameliorate symptoms associated with, e.g., type II diabetes.

US Patent:

20060014711, Jan 19, 2006

Filed:

Apr 20, 2004

Appl. No.:

10/828831

Inventors:

Ronald Evans - La Jolla CA, US
David No - Irvine CA, US
Enrique Saez - San Diego CA, US

International Classification:

A61K 48/00

US Classification:

514044000

Abstract:

In accordance with the present invention, there are provided various methods for modulating the expression of an exogenous gene in a mammalian subject employing modified ecdysone receptors. Also provided are modified ecdysone receptors, as well as homomeric and heterodimeric receptors containing sane, nucleic acids encoding invention modified ecdysone receptors, modified ecdysone response elements, gene transfer vectors, recombinant cells, and transgenic animals containing nucleic acids encoding invention modified ecdysone receptor.